

LONDON  
SCHOOL of  
HYGIENE  
& TROPICAL  
MEDICINE



Huntington, S; Hope, V; Hutchinson, S; Goldberg, D; Ncube, F  
(2006) Diversity of needle exchange provision in the UK: findings  
from a national survey. *Euro surveillance* , 11 (8). E060810.4. ISSN  
1025-496X

Downloaded from: <http://researchonline.lshtm.ac.uk/11379/>

DOI:

#### Usage Guidelines

Please refer to usage guidelines at <http://researchonline.lshtm.ac.uk/policies.html> or alternatively contact [researchonline@lshtm.ac.uk](mailto:researchonline@lshtm.ac.uk).

Available under license: <http://creativecommons.org/licenses/by/2.5/>



20  
years

1996–2016

Europe's journal on infectious disease epidemiology, prevention and control

HOME

ARCHIVES

ABOUT US

EDITORIAL POLICY


FOR AUTHORS

FOR REVIEWERS


LINKS


20-YEAR ANNIVERSARY


Search

 Submit article

 RSS Feed

 Follow us on Twitter

 Subscribe

 Unsubscribe

 Contact

 Sitemap

Announcements

EUROSURVEILLANCE IN  
OPEN ACCESS  
DIRECTORIES

Eurosurveillance remains in the updated list of the Directory of Open Access Journals (DOAJ). It was first added to the DOAJ on 9 September 2004. Eurosurveillance is also listed in the Securing a Hybrid Environment for Research Preservation and Access / Rights Metadata for Open archiving (SHERPA/RoMEO) [2], a database which uses a

Home ▶ Eurosurveillance Weekly Release 2006: Volume 11/ Issue 32 ▶ Article 4

◀ Back to Table of Contents

◀ Previous

Tweet Next ▶

## Eurosurveillance, Volume 11, Issue 32, 10 August 2006

### Articles

Citation style for this article: Huntington S, Hope V, Hutchinson S, Goldberg D, Ncube F. Diversity of needle exchange provision in the UK: findings from a national survey. Euro Surveill. 2006;11(32):pii=3022. Available online: <http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=3022>

### Diversity of needle exchange provision in the UK: findings from a national survey

S Huntington<sup>1</sup> ([susie.huntington@hpa.org.uk](mailto:susie.huntington@hpa.org.uk)), V Hope<sup>1,2</sup>, S Hutchinson<sup>3</sup>, D Goldberg<sup>3</sup>, F Ncube<sup>1</sup>

<sup>1</sup>Health Protection Agency Centre for Infections, London, United Kingdom

<sup>2</sup>Centre for Research on Drugs & Health Behaviour, London School of Hygiene and Tropical Medicine, London, United Kingdom

<sup>3</sup>Health Protection Scotland, Glasgow, United Kingdom

Needle exchanges are key to reducing transmission of bloodborne viruses (BBVs) in injecting drug users (IDUs) through the provision of sterile injecting equipment and related interventions [1]. In the United Kingdom (UK), the extent and type of service provision by needle exchanges has received little attention [2]. Information on the availability, use and coverage of harm reduction measures for IDUs is needed to help assess the effectiveness of existing, and inform the development of future, services [3]. A national survey of needle exchange facilities was

### In this issue

- ▶ Innovative new Swiss HIV prevention campaign: 'no action without protection'
- ▶ Resurgence of chikungunya virus in India: an emerging threat
- ▶ Reducing salmonella in European egg-laying hens: EU targets now set
- ▶ Diversity of needle exchange provision in the UK: findings from a national survey
- ▶ Georgios Gouvras, head of DG SANCO's Health Threats Unit

### Related articles

- ▶ A low-cost, sustainable, second generation system for surveillance of people living with HIV in Spain: 10-year trends in behavioural and clinical indicators, 2002 to 2011
- ▶ Two decades of successes and failures in controlling the transmission of HIV through injecting drug use in England and Wales, 1990 to 2011
- ▶ Outbreak of wound botulism in people who inject drugs, Norway, October to November 2013
- ▶ Anthrax among heroin users in Europe possibly caused by same

Database with associated colour-coding scheme to classify publishers according to their self-archiving policy and to show the copyright and open access self-archiving policies of academic journals. Eurosurveillance is listed there as a 'green' journal, which means that authors can archive pre-print (i.e. pre-refereeing), post-print (i.e. final draft post-refereeing) and archive the publisher's version/PDF.

**FIFTH  
EUROSURVEILLANCE  
SCIENTIFIC SEMINAR**  
ESCAIDE participants are invited to the fifth Eurosurveillance scientific seminar on 30 November 2016

**TWITTER**  
Follow Eurosurveillance on Twitter:  
[@Eurosurveillanc](#)

**ZIKA VIRUS INFECTION**  
Read our articles on Zika virus infection

**EXPRESSION OF  
CONCERN**  
Note of concern published for 'Epidemiological investigation of MERS-CoV spread in a single hospital in South Korea, May to June 2015', <http://bit.ly/29QFXPp>

[All announcements](#)



undertaken in 2005, and reports of the findings from Scotland have recently been released Scottish Executive [4]. The National Treatment Agency for Substance Misuse (NTA) has released summary finding from England and will shortly be publishing a report on the full findings [5]; results for Wales and Northern Ireland are not yet available.

The survey was initiated in response to the Department of Health's 2004 *Hepatitis C Action Plan for England* [6], and examined the extent, nature, and commissioning of needle exchange provision in the UK. Three postal questionnaires and three focus groups were used to collect quantitative and qualitative data from pharmacy exchange coordinators, non-pharmacy needle exchange providers and drug action team (DAT) coordinators, commissioning managers or their equivalents. Each country is split into DAT regions (149 in England and 22 in Scotland), which are partnerships responsible for overseeing and commissioning drug services at a local level. There was a good overall response rate, but incomplete questionnaires meant that some questions had a much lower response rate.

The survey identified 188 needle exchange facilities in Scotland, and at least 1326 in England; the total number of facilities in England could not be ascertained due to the lack of response from around a quarter of the DATs. Pharmacies made up 80% of services for which responses were received in England and 72% in Scotland. The remainder were specialist services, some of which were mobile or outreach in nature. There were only a small number of exchanges based in police custody facilities and hospital accident and emergency departments. Although there are benefits to having different types of services, both reports noted that pharmacy services should be developed to complement specialist services rather than as an alternative.

A low number of responses to questions on the distribution of injecting equipment made it difficult to estimate the national levels of needle and syringe provision. Overall, data suggested that 'on average, clients of specialist needle exchange services and pharmacy schemes were given the equivalent of approximately one syringe for every two days' [4]. Although pharmacies made up the majority of needle exchange facilities in both England and Scotland, approximately half of all syringe distribution was through pharmacy exchanges and half through non-pharmacy exchanges, with a notable variation in the amount distributed in different regions within both countries.

There was geographical variation in the types of injecting related equipment provided by services. The majority of services provided swabs, sharps bins and citric acid. English services were more likely to distribute filters, sterile water and vitamin C, while Scottish services were more likely to distribute wipes or swabs. There was also geographical variation in the provision of BBV interventions. For example, almost 80% of specialist services in northwest England reported offering hepatitis C testing, compared with under 20% in the southwest. Half of the specialist services in England offered on-site hepatitis B vaccination, compared with only 29% in Scotland. English centres were more likely to offer other BBV interventions such as testing for HIV, hepatitis C or hepatitis B (Table). However, data were not collected on the uptake of BBV

[Europe possibly caused by same Bacillus anthracis strain since 2000](#)

[Fatal case of extensively drug-resistant Mycobacterium tuberculosis Beijing genotype infection in an injecting drug user, Athens, Greece, 2012](#)

interventions and therefore it was not possible to assess the extent of BBV testing or vaccination at these services.

Table. Proportion of specialist needle exchanges offering bloodborne virus interventions in England and Scotland.

Bloodborne intervention	virus	Proportion of exchanges providing service	
		England	Scotland
Hepatitis A vaccination		25%	16%
Hepatitis B vaccination		50%	29%
HIV testing		31%	29%
Tetanus vaccine		11%	2%
Hepatitis C testing		43%	40%
Hepatitis B testing		42%	33%

A recurring theme in both reports was the inconsistency in services provided by needle exchanges. The English report concluded that 'what interventions injectors received was often not determined by their needs but by where they lived'.[5]

Transmission of BBVs among IDUs continues to be a problem in the UK [7]. It is important that needle exchanges are developed to deliver a range of services to clients, including the provision of sufficient sterile injecting equipment and other BBV interventions (such as vaccination, testing, counselling and awareness raising), and that the effectiveness of these services at preventing the spread of BBVs among IDUs are also evaluated. The reports from Scotland and England make a number of recommendations to develop standards for needle exchange services, including guidelines for paraphernalia (drug taking equipment) distribution.

#### References:

1. Des Jarlais DC, Perlis T, Arasteh K, Torian LV, Hagan H, Beatrice S, Smith L, Wethers J, Milliken J, Mildvan D, Yancovitz S, Friedman SR. Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990-2001. *AIDS*. 2005 Oct;19 Suppl 3:S20-5.
2. Parsons J, Hickman M, Turnbull PJ, McSweeney T, Stimson GV, Judd A, Roberts K. Over a decade of syringe exchange: results from 1997 UK survey. *Addiction*. 2002 Jul;97(7):845-50.
3. Wiessing LG, Denis B, Guttormsson U, Haas S, Hamouda O, Hariga F et al. Estimating coverage of harm reduction measures for injection drug users in the European Union. In: *Proceedings of 2000 Global Research Network Meeting on HIV Prevention in Drug-Using Populations. Third Annual Meeting, Durban South-Africa, 5-7 July 2000. National Institute on Drug Abuse - National Institutes of Health - U.S. Department of Health and Human Services, 2001.* (<http://www.emcdda.europa.eu/fuseaction=public.AttachmentDownload&nNodeID=1527>)

4. Scottish Executive. Needle Exchange Provision in Scotland: A report of the National Needle Exchange Survey. July 2006. Available at (<http://www.scotland.gov.uk/Publications/2006/06/16110001/0>)
5. National Treatment Agency for Substance Misuse. Findings of a survey of needle exchanges in England. London: NTA, May 2006.[Summary report] (<http://www.nta.nhs.uk>) Full report will be available at this website shortly.
6. Department of Health. Hepatitis C Action Plan for England. July 2004. (<http://www.dh.gov.uk/assetRoot/04/08/47/13/04084713.pdf>)
7. Health Protection Agency. Shooting Up: Infections among injecting drug users in the United Kingdom 2004. An update: October 2005. Available at ([http://www.hpa.org.uk/infections/topics\\_az/injectingdrugusers/menu.htm](http://www.hpa.org.uk/infections/topics_az/injectingdrugusers/menu.htm))

[back to top](#)

---

[⬅ Back to Table of Contents](#)

[⬅ Previous](#)

[Tweet](#) [Next ➡](#)

---

[↑To top](#) | [➡ Recommend this page](#)

[The publisher's policy on data collection and use of cookies.](#)

**Disclaimer:** The opinions expressed by authors contributing to *Eurosurveillance* do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the *Eurosurveillance* site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the [Creative Commons Attribution \(CC BY\) licence](#). You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN 1560-7917] - ©2007-2016. All rights reserved.



This site complies with the [HONcode standard for trustworthy health](#) information:  
[verify here](#).